PH12017500269A1 - Composite formulation for oral administration comprising omega-3 fatty acid esters and statins - Google Patents

Composite formulation for oral administration comprising omega-3 fatty acid esters and statins

Info

Publication number
PH12017500269A1
PH12017500269A1 PH12017500269A PH12017500269A PH12017500269A1 PH 12017500269 A1 PH12017500269 A1 PH 12017500269A1 PH 12017500269 A PH12017500269 A PH 12017500269A PH 12017500269 A PH12017500269 A PH 12017500269A PH 12017500269 A1 PH12017500269 A1 PH 12017500269A1
Authority
PH
Philippines
Prior art keywords
omega
fatty acid
oral administration
composite formulation
statins
Prior art date
Application number
PH12017500269A
Other versions
PH12017500269B1 (en
Inventor
Youn Woong Choi
Dae Chul Ha
Sang Min Cho
Hee Yong Song
In Ho Kwon
Seung Jin Yang
Byung Gu Min
Ah Young Kim
Original Assignee
Korea United Pharm Inc
UNITED SCIENCE R and D CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc, UNITED SCIENCE R and D CENTER filed Critical Korea United Pharm Inc
Publication of PH12017500269B1 publication Critical patent/PH12017500269B1/en
Publication of PH12017500269A1 publication Critical patent/PH12017500269A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention relates to a pharmaceutical composite formulation comprising omega-3 fatty acid ester and a statin. The composite formulation for oral administration according to the present invention comprises a statin-containing tablet, which is encapsulated into a capsule comprising an omega-3 fatty acid ester, and the formulation is thus in principle completely blocked from the external environment such as water, low pH, etc., and has advantages of exhibiting high stability, excellent disintegration rate, and dissolution rate.
PH12017500269A 2014-08-13 2017-02-13 Composite formulation for oral administration comprising omega-3 fatty acid esters and statins PH12017500269A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140105463 2014-08-13
PCT/KR2015/008523 WO2016024844A1 (en) 2014-08-13 2015-08-13 Oral combined preparation containing omega-3 fatty ester and statin-based drug

Publications (2)

Publication Number Publication Date
PH12017500269B1 PH12017500269B1 (en) 2017-07-03
PH12017500269A1 true PH12017500269A1 (en) 2017-07-03

Family

ID=55304389

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500269A PH12017500269A1 (en) 2014-08-13 2017-02-13 Composite formulation for oral administration comprising omega-3 fatty acid esters and statins

Country Status (4)

Country Link
KR (1) KR101752700B1 (en)
CN (2) CN106794149A (en)
PH (1) PH12017500269A1 (en)
WO (1) WO2016024844A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101950907B1 (en) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 Oral preparation comprising liphophilic drug and a oilproof material coated solid formulation
WO2017171484A1 (en) * 2016-03-31 2017-10-05 한미약품 주식회사 Composite preparation for oral administration containing omega-3 fatty acid or ester thereof, and hydroxymethyl glutaryl coenzyme a reductase inhibitor
KR102240935B1 (en) 2019-06-04 2021-04-15 (주) 노바렉스 Techniques for improving the disintegration and storage stability of tablet containing fingerroot extract as an active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480248B1 (en) * 2009-09-23 2015-09-02 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA3065589C (en) * 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
KR101466617B1 (en) * 2011-11-17 2014-11-28 한미약품 주식회사 ORAL COMPLEX FORMULATION COMPRISING OMEGA-3 FATTY ACID AND HMG-CoA REDUCTASE INHIBITOR WITH IMPROVED STABILITY
KR20130104059A (en) * 2012-03-12 2013-09-25 주식회사 드림파마 Pharmaceutical complex formulation for oral administration for treatment of hyperlipidenmia
WO2013169797A1 (en) * 2012-05-07 2013-11-14 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids

Also Published As

Publication number Publication date
KR20160030383A (en) 2016-03-17
PH12017500269B1 (en) 2017-07-03
KR101752700B1 (en) 2017-07-03
WO2016024844A1 (en) 2016-02-18
CN115025060A (en) 2022-09-09
CN106794149A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2021006035A (en) Stable cannabinoid formulations.
MX2012005744A (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases.
MX2016004487A (en) Enteric soft capsules comprising polyunsaturated fatty acids.
PE20161373A1 (en) DELAYED RELEASE COMPOSITIONS OF LINACHLOTID
PH12017500269B1 (en) Composite formulation for oral administration comprising omega-3 fatty acid esters and statins
TN2012000507A1 (en) Enteric tablet
TR201010683A1 (en) Vildagliptin formulations.
WO2014137797A3 (en) Stable glucokinase activator compositions
CR20150297A (en) COMICRONIZATION PRODUCT THAT INCLUDES ULIPRISTAL ACETATE
MY174729A (en) Pharmaceutical combination drug
MX2015017202A (en) Modified release formulation.
IN2014CN03214A (en)
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
IN2015DN01738A (en)
NZ715615A (en) Pharmaceutical compositions of ranolazine and dronedarone
MX2015016410A (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
MX2015015681A (en) Pharmaceutical composition comprising fingolimod.
WO2016005994A8 (en) Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
WO2014122671A3 (en) Solid oral compositions of saxagliptin
NZ628867A (en) Pharmaceutical formulation containing flupirtine
IN2014MU01179A (en)
MX2016016260A (en) New solid forms of sitagliptin.
PL410457A1 (en) Pharmaceutical composition containing docosahexanoic acid and its application